A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
With
Biogen
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients 18-80 years of age with active RA;
patients who participated in MabThera study WA17042, and completed to at least the Week 24 visit;
eligible for re-treatment, based on clinical symptoms;
patients of reproductive potential must be using reliable contraceptive methods.
You may not be if
patients who participated in MabThera study WA17042 but withdrew into the safety follow-up;
current treatment with any other disease-modifying antirheumatic drug (apart from methotrexate), or any anti-TNFalfa, anti-IL1, or other biologic therapies;
development of any new contraindications to receiving MabThera;
women who are pregnant or breast-feeding.
Clareo Health | A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies
